H
Hernán Cortés-Funes
Researcher at Complutense University of Madrid
Publications - 200
Citations - 7240
Hernán Cortés-Funes is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 45, co-authored 199 publications receiving 6963 citations. Previous affiliations of Hernán Cortés-Funes include Hospital General Universitario Gregorio Marañón & Hospital de Sant Pau.
Papers
More filters
Journal ArticleDOI
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Jose Baselga,Jose Manuel Trigo,Jean Bourhis,Jacques Tortochaux,Hernán Cortés-Funes,Ricardo Hitt,Pere Gascón,Nadia Amellal,Andreas Harstrick,André Eckardt +9 more
TL;DR: The combination of cetuximab and platinum chemotherapy is an active and well-tolerated approach to the treatment of this poor-prognosis patient population with platinum-refractory recurrent or metastatic SCCHN for whom there are no recommended standard therapeutic options.
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer
Ricardo Hitt,Antonio Lopez-Pousa,Javier Martinez-Trufero,Vicente Escrig,Joan Carles,Alfredo Rizo,Dolores Isla,M. Eugenia Vega,Juan Luis Gomez Marti,Francisco Lobo,Pedro Pastor,Vicente Valentí,J. Belon,Miguel Ángel Martín Sánchez,Carlos Chaib,Cinta Pallares,Antonio Antón,Andrés Cervantes,Luis Paz-Ares,Hernán Cortés-Funes +19 more
TL;DR: Induction chemotherapy with PCF was better tolerated and resulted in a higher CR rate than CF, and new trials that compare induction chemotherapy plus CRT versus CRT alone are needed to better define the role of neoadjuvant treatment.
Journal ArticleDOI
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
Ricardo Hitt,Juan J. Grau,Antonio Lopez-Pousa,A. Berrocal,C. García-Girón,A. Irigoyen,Javier Sastre,Javier Martinez-Trufero,J.A. Brandariz Castelo,E. Verger,Juan J. Cruz-Hernández,C. Almodóvar,Hernán Cortés-Funes,Y. Escobar,E. Fonseca-Sánchez,J. C. Galceran,M. Guix,D. Isla-Casado,C. Jara-Sánchez,M.R. Leitão-Silva,J.R. Mel-Lorenzo,M. Pastor-Borgoñón,P. Pastor-Gaitán,A. Rodríguez-Jaráiz,J.M. Millán,J. Satrustegui-Galdona,M. Moreno,E. Estefanía,E. Santiago,Juan José García +29 more
TL;DR: This trial failed to show any advantage of ICT-CCRT over CCRT alone in patients with unresectable LASCCHN, and there were no statistically significant differences for overall survival (OS).
Journal ArticleDOI
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Stefan Aebi,S. Gelber,M. Castiglione-Gertsch,Richard D. Gelber,J. Collins,Beat Thürlimann,C. M. Rudenstam,J. Lindtner,Diana Crivellari,Hernán Cortés-Funes,Edda Simoncini,I. D. Werner,Alan S. Coates,A. Goldhirsch +13 more
TL;DR: The endocrine effects of chemotherapy alone are insufficient for the younger age group and these patients should strongly consider additional endocrine therapies (tamoxifen or ovarian ablation) if their tumours express oestrogen receptors.
Journal ArticleDOI
Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
Eduardo Díaz-Rubio,Javier Sastre,Alberto Zaniboni,Roberto Labianca,Hernán Cortés-Funes,F. de Braud,Corrado Boni,Manuel Benavides,G. Dallavalle,M. Homerin +9 more
TL;DR: Oxaliplatin is an active agent in first-line chemotherapy for advanced colorectal cancer and was well tolerated, caused no toxic deaths, had low hematotoxicity, well controlled gastrointestinal toxicity, and frequent but mild peripheral neurological symptoms.